Abstracts tagged "autoimmune diseases"

Abstract Number: 1361 • ACR Convergence 2022
Factors Associated with Medication-Free Remission in Juvenile Dermatomyositis
Harneet Ghumman¹, Asra Firdous¹, Megan Quinlan-Waters¹, Amy Cassedy², Angela Merritt¹, Hermine Brunner³, Alexei Grom¹, Daniel Lovell¹ and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cleveland, OH, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis and multi-organ involvement. Treatment with systemic immunosuppression…
Abstract Number: 1652 • ACR Convergence 2022
Long-term Safety and Efficacy of Anifrolumab in Adult Patients with Systemic Lupus Erythematosus: A Multicenter, Randomized, Double-blind, Placebo-controlled 3-year TULIP Extension Study
Kenneth C. Kalunian¹, Richard A. Furie², Eric F. Morand³, Ian N. Bruce⁴, Susan Manzi⁵, Yoshiya Tanaka⁶, Kevin Winthrop⁷, Gabriel Abreu⁸, Ihor Hupka⁹, Lijin Zhang¹⁰, Shanti Werther¹¹, Micki Hultquist¹², Raj Tummala¹⁰ and Catharina Lindholm¹¹, ¹UC San Diego, La Jolla, CA, ²Northwell Health, Great Neck, NY, ³Monash University, Melbourne, Australia, ⁴The University of Manchester, Manchester, United Kingdom, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁷Oregon Health & Science University, Portland, OR, ⁸AstraZeneca, Mölndal, Sweden, ⁹AstraZeneca, Warsaw, Poland, ¹⁰AstraZeneca, Gaithersburg, MD, ¹¹AstraZeneca, Gothenburg, Sweden, ¹²AstraZeneca, Bethesda, MD
Background/Purpose: Anifrolumab is a fully human IgG1 κ monoclonal antibody that binds to the type I IFN receptor and inhibits type I IFN signaling.1 In…
Abstract Number: 1845 • ACR Convergence 2022
Mortality Prognostic Factors of Critically Ill Patients with Systemic Autoimmune Diseases Admitted in a Medical Intensive Care Unit: A 20-year Cohort Study
Pamela Doti¹, Ana Luisa Cunha², Armin Quispe Cornejo³, Ángela Nieto González¹, Andre Matos¹, Pedro Guevara Hernández¹, Pedro Castro Rebollo¹ and Gerard Espinosa Garriga¹, ¹Hospital Clínic, Barcelona, Spain, ²Hospital Senhora da Oliveira, Guimarães, Porto, Portugal, ³Erasme Hospital, Brussels, Belgium
Background/Purpose: To describe the clinical characteristics of a 20-year cohort of patients with systemic autoimmune diseases (SAD) admitted to a medical intensive care unit (ICU)…
Abstract Number: 2185 • ACR Convergence 2022
Development of a Novel Regulatory T Cell-Based Therapy for Patients with Rheumatoid Arthritis
Anne-Renee van der Vuurst de Vries¹, Kathryn Hooper¹, Jonathan Graf², Katie Tuckwell¹ and Joshua Beilke¹, ¹Sonoma Biotherapeutics, South San Francisco, CA, ²Ucsf, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory condition with persistent unmet medical need despite significant treatment advances. The pathogenesis of RA is initiated…
Abstract Number: 0014 • ACR Convergence 2022
The Expanded CD21 Low B Cell Subpopulation in Ankylosing Spondylitis Consists Mainly of Antigen-Inexperienced Cells
Rick Wilbrink¹, Linda van der Weele², Anneke Spoorenberg¹, Niek De Vries², Frans Kroese¹ and Gwenny Verstappen¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University Medical Center Amsterdam, Amsterdam, Netherlands
Background/Purpose: The role of B cells in the pathogenesis of ankylosing spondylitis (AS) remains relatively understudied. Nevertheless, available evidence shows presence of B cells at…
Abstract Number: 0157 • ACR Convergence 2022
Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale
Rohit Aggarwal¹, Brendan Johnson², Jolie Feldman³, Austin Gromatzky⁴ and Paul N Mudd Jr.², ¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Priovant Therapeutics, Durham, NC, ³Priovant Therapeutics, New York, NY, ⁴Priovant Therapeutics, Washington, DC
Background/Purpose: Brepocitinib is a novel, orally available, TYK2/JAK1 inhibitor in Phase 3 development for the treatment of dermatomyositis (DM), a chronic immune-mediated disease of the…
Abstract Number: 0506 • ACR Convergence 2022
Immunophenotypic Categorization of Systemic Immune-mediated Diseases
Shinji Izuka¹, Toshihiko Komai¹, Takahiro Itamiya¹, Mineto Ota², Saeko Yamada¹, Yasuo Nagafuchi², Hirofumi Shoda¹, Kosuke Matsuki³, Kazuhiko Yamamoto⁴, Tomohisa Okamura² and Keishi Fujio¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo City, Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Bunkyo City, Tokyo, Japan, ³Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan, ⁴Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, the Institute of Physical and Chemical Research (RIKEN), Wako, Saitama, Japan
Background/Purpose: Systemic immune-mediated diseases are heterogeneous, and the pathogenesis varies among and within each disease. Some studies tried to stratify patients with immune-mediated diseases into…
Abstract Number: 0645 • ACR Convergence 2022
Lupus Fibroblasts from Non-lesional Skin Exhibit Exaggerated Responses to Inflammatory Cytokines and Upregulate Pro-fibrotic Collagens in Patients with Scarring Lesions
Suzanne Shoffner-Beck, Lisa Abernathy-Close, Stephanie Lazar, Amy Hurst, Craig Dobry, Deepika Pandian, Rachael Wasikowski, Kelly Arnold, Johann Gudjonsson, Lam Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a manifestation of systemic lupus erythematosus (SLE) that can cause significant patient distress and disfiguration secondary to scar. Scarring…
Abstract Number: 0740 • ACR Convergence 2022
Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Secondary Hemophagocytic Lymphohistiocytosis in the United States: The REAL-HLH Study
Carl Allen¹, Shanmuganathan Chandrakasan², Michael Jordan³, Jennifer Leiding⁴, Abiola Oladapo⁵, Priti Pednekar⁶, Kelly Walkovich⁷ and John Yee⁸, ¹Baylor College of Medicine, Houston, TX, ²Emory University School of Medicine, Atlanta, GA, ³University of Cincinnati, Cincinnati, OH, ⁴Johns Hopkins University, Baltimore, MD, ⁵Swedish Orphan Biovitrum AB, Boston, MA, ⁶PRECISIONheor, Los Angeles, CA, ⁷University of Michigan Health, Ann Arbor, MI, ⁸Sobi - North America, Waltham, MA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening, hyperinflammatory syndrome caused by overproduction of proinflammatory cytokines, e.g., interferon gamma (IFNγ). Secondary HLH (sHLH), a subtype…
Abstract Number: 0790 • ACR Convergence 2022
Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study
Omar Alsaed, Masautso Chaponda, Eman Satti, Hadil Ashour, Muna Almaslamani and Samar Al emadi, Hamad Medical Corporation, Doha, Qatar
Background/Purpose: The sustainability of the immunogenicity of BNT162b2 anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients with autoimmune rheumatic diseases (ARDs) receiving immunomodulators…
Abstract Number: 0987 • ACR Convergence 2022
A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases
Stacey Dillon¹, Pille Harrison², Jason Lickliter³, Kristi Manjarrez¹, Alina Smith¹, Mary Lessig¹, Lori Blanchfield¹, Russell Sanderson¹, Allison Chunyk¹, Tiffany Blair¹, Amanda Enstrom¹, Martin Wolfson¹, Mark Rixon¹, Hany Zayed⁴, Rupert Davies¹ and Stanford Peng¹, ¹Alpine Immune Sciences, Seattle, WA, ²Alpine Immune Sciences, Taunton, United Kingdom, ³Nucleus Network, Melbourne, Australia, ⁴Alpine Immune Sciences, San Francisco, CA
Background/Purpose: B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are tumor necrosis factor (TNF) superfamily members that bind TACI (transmembrane activator and CAML…
Abstract Number: 1200 • ACR Convergence 2022
Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial: Outcomes over 7 Years
Karen Costenbader¹, Nancy R Cook², I-Min Lee², Jill Hahn³, Joseph Walter¹, Vadim Bubes¹, Gregory Kotler¹, Nicole Yang¹, Sonia Friedman¹, Erik K Alexander¹ and JoAnn E Manson², ¹Brigham and Women's Hospital, Boston, MA, ²Harvard TH Chan School of Public Health, Brigham and Women's Hospital, Boston, MA, ³Brigham and Womens' Hospital, Boston, MA
Background/Purpose: Strong biologic rationale supports potential effects of both vitamin D and of marine omega-3 (n3) fatty acids for autoimmune disease prevention. Within the randomized…
Abstract Number: 1363 • ACR Convergence 2022
Impact of SARS-CoV-2 on the Clinical Presentation of Juvenile Idiopathic Inflammatory Myopathies
Jessica Perfetto¹, Donna Yoo², Carolina Tamashiro³, Megan Perron⁴, Natalia Vasquez Canizares⁵ and Dawn Wahezi⁶, ¹The Children's Hospital at Montefiore, Division of Rheumatology, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³The Children's Hospital at Montefiore, Department of Pediatrics, Bronx, NY, ⁴Children's Hospital Colorado, Division of Rheumatology, Aurora, CO, ⁵Children's Hospital at Montefiore/ Albert Einstein College of Medicine, New York, NY, ⁶Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: Viruses can trigger juvenile idiopathic inflammatory myopathies (JIIM), including juvenile dermatomyositis (JDM), juvenile polymyositis (JPM), and overlap myositis. There is growing evidence that infection…
Abstract Number: 1662 • ACR Convergence 2022
Nationwide Distribution of Other Connective Tissue Disease (OCTD) and Systemic Sclerosis (SSc) in Areas of Environmental Concern
Noelle Kosarek¹, Megan Romano², Robert Simms³, Angeline Andrew⁴, Erika Moen⁴, Patricia pioli⁴ and Michael Whitfield⁵, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁵Dartmouth Geisel School of Medicine, Department of Biomedical Data Science, Lebanon, NH
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs, vascular abnormalities, and autoantibody formation. The etiology…
Abstract Number: 1848 • ACR Convergence 2022
Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope
Josh Dan¹, Grant Sprow², Josef Concha³, Nilesh Kodali⁴, DeAnna Diaz⁵, Felix Chin⁶, Thomas Vazquez⁷ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Albert Einstein College of Medicine, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴New Jersey Medical School, Coppell, TX, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁷FIU Wertheim College of Medicine, Virginia Beach, VA
Background/Purpose: Nailfold capillary (NC) abnormalities are increasingly utilized in the evaluation of rheumatic conditions. Their presence can distinguish primary Raynaud's phenomenon from secondary etiologies and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].